Journal article
Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*
P Quaglino, HM Prince, R Cowan, M Vermeer, E Papadavid, M Bagot, O Servitjie, E Berti, E Guenova, R Stadler, C Querfeld, AM Busschots, E Hodak, A Patsatsi, J Sanches, M Maule, J Yoo, M Kevin, P Fava, S Ribero Show all
British Journal of Dermatology | WILEY | Published : 2021
DOI: 10.1111/bjd.19252
Abstract
Background: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods: In total, 395 newly diagnosed patients with early-stage MF (stage IA–IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopath..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by Cancer Research UK (50763/A18021; to J.J.S.); the European Academy of Dermatology and Venereology (2014-23; to J.J.S.); the Spatz Foundation, Sundown Endowment Legacy (to Y.K.); Krebsliga Schweiz (KFS-4243-08-2017; to E. Guenova); Promedica Stiftung 1406/M and 1412/M (to E. Guenova); Fondo de Investigacion para la Salud (PI17/00957; to P.O.-R.); and an NIH/NCI Cancer Center Support Grant (P30CA033572) to the City of Hope, NIH/NCI grant (R01 CA229510-01) and Leukemia Lymphoma Society Clinical Scholar Award (CDP-14110-18; to C.Q.).